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Abstract
Background: Ramosetron is a relatively new 5-hydroxytryptamine three receptor antagonist with higher binding
affinity and more prolonged duration of action compared to ondansetron. The present study was performed to
evaluate the effects of ramosetron on QTc interval and possible cardiovascular adverse effects in patients
undergoing cardiac surgery.
Method: A total of 114 patients who underwent off-pump coronary artery bypass surgery were enrolled in this
randomised placebo-controlled trial. Patients were allocated into two groups that received intravenous injection of
0.3 mg ramosetron or normal saline during induction of anaesthesia. QTc intervals were measured before the
operation, intraoperatively (0, 1, 2, 3, 5, 10, 15, 30, 45, 60, 90, 120, and 240 min after injection of ramosetron or
normal saline), at the end of the operation, and on postoperative day 1.
Results: There were no differences in mean QTc interval between groups at every time point. However, maximal change
in QTc interval during surgery was higher in the ramosetron group than the placebo group (25.1 ± 22.0 vs. 17.5 ± 14.5 ms,
95 % CI 0.34–14.78, P = 0.040). Also, there were more patients with a QTc interval increase of > 60 ms in the ramosetron
group (5 vs. 0, 95 % CI 1.6–18.0, P = 0.021). There were no significant differences in cardiovascular complications.
Conclusions: Ramosetron administered during induction of anaesthesia may affect maximal change in QTc interval
during off-pump coronary artery bypass surgery. Ramosetron should be used with caution in high risk patients for
developing Torsades de Pointes.
Trial registration: ClinicalTrials.gov NCT02139241. Registered November 12, 2013
Keywords: Cardiac surgery, Corrected QT interval, Ramosetron, Torsadogenic action, Serotonin 5-HT3 receptor antagonists
Backgroud
5-Hydroxytryptamine 3 (5-HT3) receptor antagonists are
widely used antiemetics for postoperative nausea and
vomiting (PONV). However, QTc interval prolongation has
been observed in a number of patients after administration
of 5-HT3 receptor antagonists, such as ondansetron [1, 2].
QTc interval prolongation increases the likelihood of poly-
morphous ventricular arrhythmia or Torsades de Pointes
(TdP), which may progress to fatal ventricular fibrillation
and sudden death [3]. Previous studies showed that QTc
interval prolongation is associated with increased risk of
cardiovascular mortality and sudden cardiac death [4–6].
PONV is not a rare occurrence in cardiac surgery pa-
tients, with incidence rates of 35 to 71 % [7]. Long dur-
ation of anaesthesia, postoperative pain, and high levels
of opioid use may contribute to PONV in cardiac sur-
gery [8]. 5-HT3 receptor antagonists have been used in
various clinical settings, including cardiac surgery. How-
ever, patients with organic heart disease are likely to
have QTc interval prolongation [9], thus 5-HT3 receptor
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antagonist-associated prolongation of QTc interval in
high-risk cardiac surgical patients may further increase
QTc interval and may result in severe cardiac
complications.
Ramosetron is relatively new 5-HT3 receptor antagon-
ist, which has higher binding affinity and prolonged dur-
ation of action compared with ondansetron [10]. A
recent meta-analysis showed that ramosetron is effective
for preventing PONV and reduces the incidence of
PONV compared with ondansetron [11]. However, lim-
ited data are available regarding whether ramosetron in-
creases QTc interval. As 5-HT3 receptor antagonists
share a mechanism of action, we hypothesised that
ramosetron would be associated with QTc interval pro-
longation in patients undergoing cardiac surgery. To
evaluate our hypothesis, we conducted a prospective,
randomised, double-blind, placebo-controlled study with
evaluation of QTc interval and cardiovascular adverse
outcomes by ramosetron in patients undergoing off-
pump coronary artery bypass graft (OPCAB).
Methods
Patients
This trial was registered at clinicalTrials.gov (NCT02139241)
and adhered to CONSORT guidelines. The study
complied with the Declaration of Helsinki and each
patient gave his or her written consent to participate.
There were no important changes to methods or out-
comes after trial commencement and no interim ana-
lyses were performed. Adult patients scheduled for
elective OPCAB were eligible for inclusion. Patients
were excluded if they had preoperative treatment with
inotropic agents or mechanical assist devices, heart
failure with left ventricular ejection fraction less than
30 %, QTc interval prolongation of more than 500 ms
on preoperative ECG, significant arrhythmia including
atrial fibrillation or atrioventricular block, age more
than 80 years, a history of hepatic failure (Child Class
B or C), emergency operation, renal impairment re-
quiring renal replacement therapy, history of allergy
to 5-HT3 antagonists, recent exposure to medications
known to cause QTc prolongation, or undergone con-
comitant major surgeries including general surgery,
neurosurgery and orthopaedic surgery.
Study design and treatments
The study was double-blind, placebo-controlled, parallel-
group study conducted in Seoul National University
Hospital, a tertiary hospital in Seoul, Korea. Patients were
randomly allocated to either ramosetron group or placebo
group, using a computer-generated random number table.
A randomisation sequence was created with a 1:1 alloca-
tion using random block sise of 4. An independent nurse
who was not involved in the collection of data and patient
care handled the random list. All patients, medical
personnel, and investigators were blinded to the alloca-
tion. One researcher (D.M.H.) generated the random allo-
cation sequence, enrolled participants and assigned
participants to interventions. The independent nurse pre-
pared 0.3 mg of ramosetron (Nasea®; Astellas, Tokyo,
Japan), the manufacturer’s recommended dose or, for the
control group, the same volume of normal saline.
These two medications of the same color and volume
were indistinguishable to the anaesthesiologists in charge
of anaesthesia. The ramosetron group received intraven-
ous ramosetron immediately before induction of general
anaesthesia, while the placebo group received intraven-
ous normal saline according to the same schedule.
Anaesthesia
All patients received standard perioperative care. Rou-
tine monitoring included 5-lead ECG, pulse oximetry,
non-invasive blood pressure, bispectral index, cerebral
oximetry, continuous arterial blood pressure, pulmonary
artery catheter, and transoesophageal echocardiography.
A radial arterial catheter was put in place under local
anaesthesia with lidocaine. Anaesthesia was induced with
intravenous midazolam 0.15 mg/kg, sufentanil 1 μg/kg,
and vecuronium 0.15 mg/kg, and maintained with con-
tinuous infusions of remifentanil 0.5–1.0 μg/kg/min and
propofol 0.04–0.07 mg/kg/min, with targeting bispectral
index values between 40 and 60. We did not use volatile
anaesthetics to avoid their effects on QTc interval [12–
14]. Arterial systolic, diastolic, and mean blood pressure,
heart rate, and doses of inotropic or anticholinergic
drugs were recorded at the time of induction and during
the surgery. Anaesthesia-related hypotension (mean
blood pressure < 60 mmHg) was treated with either
ephedrine 0.1 mg/kg IBW (ideal body weight) (heart
rate < 70 beats/min) or phenylephrine 0.5 μg/kg IBW
(heart rate ≥ 70 beats/min). If blood pressure was not re-
stored within 30 s, the regimen was repeated until the
maximum dose of ephedrine 0.5 mg/kg IBW or phenyl-
ephrine 4 μg/kg IBW was reached. If the blood pressure
was not restored by the maximum dose, vasopressin or
epinephrine was administered at the anaesthesiologist’s
discretion. Normothermia was maintained during the
surgery with a heating mattress, warmed intravenous
fluids, and a warm operating room temperature.
QTc interval measurement and analysis
Digital ECGs were recorded using a continuous moni-
toring ECG system (Solar® 8000 M, GE Medical Systems,
Milwaukee, WI, USA) at the beginning of drug adminis-
tration, after 1, 2, 3, 5, 10, 15, 30, 45, 60, 90, 120, and
240 min, and at the end of the operation. ECG data in
lead II were extracted with an analogue-to-digital con-
verter (DI-149; DATAQ Instruments Inc., Akron, OH,
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USA), which was connected to the analogue output of
the patient monitor, and stored on a personal computer
[15]. Lead placement was consistent in the tracing of
ECG. Temporally aligned superimposed ECG leads were
available as an optional display. The sampling rate was
1000 Hz. At first, the QT interval was measured using a
computer-based data analysis system (LabChart7; ADI
Instruments, Colorado Springs, CO, USA). ECG waves
of the four consecutive cycles were averaged to acquire a
more accurate representation of the ECG waveform. The
QT interval was corrected according to Bazett’s formula
to preclude interference from heart rate (QTc =QT/RR1/
2). Additionally, QT interval was corrected using Frideri-
cia’s formula (QTc = QT / RR1/3) and Hodges formula
(QTc = QT + 1.75 (heart rate – 60)). An investigator
(T.K.K.) blinded to the group allocations reviewed the
ECG data and checked for possible artifacts. Noise or
abnormal ECG rhythms were excluded from the QTc
interval measurement. After the operation, patients were
checked for arrhythmias, including atrial fibrillation,
atrial flutter, ventricular tachycardia, ventricular fibrilla-
tion, bradycardia (heart rate < 50 beats/min), and tachy-
cardia (heart rate > 100 beats/min). A postoperative ECG
was performed to evaluate QTc interval on the morning
of postoperative day 1.
Definition of postoperative complications
The lengths of stay in the ICU and hospital were defined
as the difference in days between the date of discharge
and the date of surgery. Postoperative in-hospital major
adverse cardiovascular and cerebral events (MACCE)
were defined as a composite of death from cardiac causes,
myocardial infarction, unplanned coronary revascularisa-
tion, and stroke. Myocardial infarction was defined as ele-
vation of troponin values (>10 × 99th percentile upper
reference limit) in patients with normal baseline troponin
values (<99th percentile upper reference limit). In
addition, new pathological Q waves, new left bundle
branch block, angiographically documented new graft or
new native coronary artery occlusion, or imaging evidence
of new loss of viable myocardium or new regional wall
motion abnormality were required. Unplanned coronary
revascularisation was defined as unplanned repeat percu-
taneous coronary intervention or CABG. Stroke was de-
fined as a new ischaemic or haemorrhagic cerebrovascular
accident with a neurological deficit lasting > 24 h.
Statistical analysis
The primary endpoint was maximal intraoperative
change in QTc interval after administration of ramose-
tron or placebo. The secondary endpoints were number
of patients with QTc interval > 500 ms, which is consid-
ered to increase the risk of TdP [16]; number of patients
with QTc interval increase > 60 ms, which is also
considered to increase the risk of TdP [17]; presence of
hypotension and bradycardia during anaesthesia induc-
tion; use of vasopressors or inotropes; presence of post-
operative in-hospital arrhythmia and MACCE. Our pilot
study showed that maximal change in QTc interval was
15 ± 15 ms during OPCAB. Presuming that the differ-
ence of 10 ms in the QTc intervals was clinically signifi-
cant, power analysis suggested that a minimum of 49
patients would be required for each group with a type 1
error of 0.05 and a power of 0.9. Considering a 15 %
dropout rate, 114 patients were recruited. Comparisons
of age, weight, height, body mass index, anaesthesia
time, serum electrolytes, blood pressure, heart rate, pre-
operative and maximal change in QTc interval, and
lengths of stay in the ICU and hospital were tested with
Student’s t-test or Mann–Whitney U-test after testing
for normality. Sex, previous medical history, use of vaso-
pressors or inotropes, presence of prolonged QTc inter-
val, and presence of postoperative complications were
compared by the Chi-square test or Fisher’s exact test
where appropriate. QTc intervals taken serially after in-
duction, heart rate, and blood pressure were analysed
using repeated measures analysis of variance for inter-
and intra-group comparisons. Statistical analyses were
performed using the SPSS software (ver. 21.0; SPSS Inc.,




A total of 140 consecutive patients treated from June
2013 to October 2014 were enrolled in this study. Of
the 140 patients, 26 were excluded; 10 for left ven-
tricular ejection fraction < 30 %, 10 for atrial fibrilla-
tion or atrioventricular block, and six for renal
impairment requiring renal replacement therapy
(Fig. 1). Of the 114 randomised patients, data from
11 patients could not be analysed because of poor
ECG data quality or data loss. There were no cases of
conversion to on-pump from OPCAB. Most surgeries
began at around the same time in the morning
(87.5 %); the case start time was not different be-
tween the groups. The nadir body temperature was
not different between the groups (P = 0.106). Table 1
summarises the patients’ baseline characteristics. Pre-
operative bradycardia, QTc interval on ECG, and
serum electrolyte levels of calcium and potassium
were not significantly different between the groups.
Perioperative haemodynamic parameters
The changes in heart rate and mean arterial pressure
over time were significant in both ramosetron and pla-
cebo groups (P < 0.001 and P < 0.001, respectively)
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Fig. 1 Consort diagram of study participants
Table 1 Characteristics of patients receiving ramosetron or placebo
Ramosetron (n = 51) Placebo (n = 52)
Male sex 42 (82.4 %) 40 (76.9 %)
Age (years) 66.8 ± 9.4 66.0 ± 9.9
Weight (kg) 66.0 ± 11.1 63.5 ± 10.3
Height (cm) 164.5 ± 9.3 162.0 ± 8.2
Body mass index (kg/m2) 24.4 ± 3.0 24.1 ± 3.0
Hypertension 37 (72.5 %) 33 (63.5 %)
Diabetes mellitus 22 (43.1 %) 17 (32.7 %)
1-Vessel disease 0 (0.0 %) 4 (7.7 %)
2-Vessel disease 6 (11.8 %) 8 (15.4 %)
3-Vessel disease 45 (88.2 %) 40 (76.9 %)
Previous myocardial infarction 3 (5.9 %) 4 (7.7 %)
Previous stroke 3 (5.9 %) 4 (7.7 %)
Current smoker 11 (21.6 %) 9 (17.3 %)
Sodium (mEq/l) 138.6 ± 3.7 139.1 ± 2.9
Potassium (mEq/l) 4.1 ± 0.4 4.0 ± 0.4
Bradycardia (heart rate <50 beats/min) 2 (4.0 %) 2 (3.9 %)
Left ventricle ejection fraction
> 49 % 48 (94.1 %) 48 (92.3 %)
30–49 % 3 (5.9 %) 4 (7.7 %)
< 30 % 0 (0.0 %) 0 (0.0 %)
Preoperative QTc interval (ms) 430.7 ± 33.6 425.2 (29.7)
Preoperative QTc interval > 500 ms 0 (0.0 %) 0 (0.0 %)
Congenital long QT syndrome 0 (0.0 %) 0 (0.0 %)
Duration of anaesthesia (min) 449.7 ± 44.2 451.4 ± 68.0
Data are presented as mean ± SD or number (proportion)
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(Fig. 2), but were not different between the groups (P =
0.210 and P = 0.178, respectively). There were no inter-
group differences regarding the use of ephedrine or
phenylephrine during anaesthesia induction (P = 0.208,
and 0.603, respectively), the use of inotropes or vaso-
pressors at the end of surgery (P = 1.000, and 1.000, re-
spectively), or total amount of infused fluid during the
surgery (P = 0.666) (Table 2).
Perioperative QTc interval
The changes in mean intraoperative QTc interval over
time were not different between the groups (P = 0.591,
Fig. 3). However, maximal change in QTc interval during
surgery was higher in the ramosetron group than the
placebo group (mean difference 7.56 ms, 95 % CI 0.34–
14.78, P = 0.040, Fig. 4). The peak effect of ramosetron
on QTc was observed at [median (IQR), 5 (2–30)] min
after anaesthesia induction. Prolongation of QTc inter-
val > 500 ms was not significantly different between
groups. However, the number of patients with QTc
interval increase > 60 ms was higher in the ramosetron
group (risk difference 9.8 %, 95 % CI 1.6–18.0, P = 0.021)
(Table 3). Five patients with an increase in QTc > 60 ms
had baseline QTc values of 381.4 ± 36.0 ms, whereas the
patients with QTc ≤ 60 ms had baseline QTc values of
397.0 ± 18.6 ms (P = 0.086). When applying the Hodges
formula, maximal change in QTc interval was higher in
the ramosetron group with a marginal significance
(mean difference 8.81 ms, 95 % CI −0.99–18.61, P =
0.077). Also, there were more patients with a QTc inter-
val increase of > 60 ms in the ramosetron group (risk dif-
ference 9.8 %, 95 % CI 1.6–18.0, P = 0.021) (Additional
file 1 shows QTc interval by Fridericia’s formula and
Hodges formula). None of the patients experienced
Fig. 2 Heart rate (a) and mean arterial pressure (b) during surgery. Values are shown as means (SD). * P < 0.05 compared to baseline
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clinically significant arrhythmias requiring treatment
during surgery.
Postoperative in-hospital complications
There were no significant differences between the
groups in the incidences of postoperative arrhythmias,
including atrial fibrillation, atrial flutter, ventricular
tachycardia, ventricular fibrillation, bradycardia, and
tachycardia (Table 4). The lengths of stay in the in-
tensive care unit (ICU) and hospital, all components
of MACCE, including death from cardiac causes,
myocardial infarction, unplanned coronary revasculari-
sation, and stroke, were not different between the
groups (Table 4). However, this study was not
powered to assess the effect of ramosetron on postop-
erative complications.
Discussion
In the present study, 0.3 mg of intravenous ramosetron
was associated with a significant increase of maximal
change in QTc interval during OPCAB. Also, increase of
the QTc interval of more than 60 ms, which is considered
to increase the risk of TdP was more frequently observed
in the ramosetron group. There were no statistically sig-
nificant differences in the intraoperative haemodynamic
variables measured.
Most QTc interval prolonging drugs act by blocking the
potassium channel encoded by the human ether-a-go-go-
related gene (hERG) [18]. 5-HT3 antagonists share the
same potential proarrhythmic mechanisms. However, not
all drugs in the 5-HT3 antagonist class have clinically sig-
nificant QTc-interval-prolonging effects. Ondansetron pro-
duced dose-related prolongation of QTc interval [1, 2], but
granisetron and palonosetron did not induce significant
Table 2 Haemodynamic variables and fluids administered during surgery
Ramosetron (n = 51) Placebo (n = 52) P value
Before anaesthesia induction
Baseline heart rate (beats/min) 66.1 ± 10.6 68.3 ± 11.7 0.317
Baseline mean arterial pressure (mmHg) 96.3 ± 15.8 101.1 ± 14.6 0.117
During anaesthesia induction
Use of ephedrine 37 (72.5 %) 31 (60.8 %) 0.294
Use of phenylephrine 8 (15.7 %) 10 (19.6 %) 0.796
At the end of surgery
Use of vasopressors 1 (1.9 %) 1 (2.0 %) 1.000
Use of inotropes 1 (1.9 %) 1 (2.0 %) 1.000
Number of grafts (n) 3.6 ± 0.7 3.3 ± 1.1 0.120
Total infused fluids (ml) 3671.2 ± 1368.4 3557.1 ± 1308.9 0.666
Total infused crystalloids (ml) 3083.3 ± 1699.3 2992.5 ± 1612.8 0.781
Total infused colloids (ml) 585.9 ± 638.7 526.2 ± 814.6 0.680
Data are presented as mean ± SD or number (proportion)
Fig. 3 QTc interval during surgery. Values are shown as means (SD)
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QTc interval prolongation [19, 20]. There are limited data
regarding the effects of ramosetron on QTc interval in
high-risk patients undergoing cardiac surgery.
Postoperative QTc interval prolongation was observed in
80 % of patients undergoing noncardiac surgery [21]. Mul-
tiple drugs, including opioids, general anaesthetics, antibi-
otics, and cardioactive drugs, are associated with QT
prolongation. In a recent study, QTc interval prolongation
was common in patients undergoing cardiothoracic sur-
gery [22]. However, this report did not describe the method
of anaesthesia including the use of volatile anaesthetics,
which prolong QTc interval and confound the effects of 5-
HT3 antagonists on QTc interval [12–14]. In the present
study, general anaesthesia was maintained during surgery
using continuous infusion of propofol and remifentanil,
which are known to have minimal effects on QTc interval
[14]. Mean intraoperative QTc intervals did not increase
compared to baseline QTc value in both the ramosetron
and placebo groups (Fig. 3). A previous study indicated
that tracheal intubation caused significant prolongation of
QTc interval during the anaesthetic induction period due
to sympathetic stimulation [23]. However, in this study,
tracheal intubation was performed 7.6 ± 1.6 min after ad-
ministration of ramosetron or placebo, and it did not
significantly prolong QTc interval (Fig. 3). Sufentanil ad-
ministered during anaesthetic induction may attenuate the
sympathetic stimuli during tracheal intubation [24].
A recent study concluded that mean QTc interval
did not increase after ramosetron administration in
adult patients undergoing laparoscopic cholecystec-
tomy, which was consistent with our results [25].
However, they did not compare the maximal changes
in QTc interval. In this observational trial, the QTc
interval was measured only during the last 10 min of
surgery. To the best of our knowledge, there have
been no randomised placebo controlled studies to in-
vestigate the effects of ramosetron on the QTc inter-
val throughout the surgery.
In the present study, there were no differences in
mean QTc interval between the ramosetron group
and placebo group at every time point (Fig. 3). There
were no differences in the measured intra- or post-
operative outcomes. It is possible that the effect of
QTc prolongation may not be so strong to be clinic-
ally significant. However, ramosetron increased the
maximal change in QTc interval during the surgery,
and there were more patients with a QTc interval in-
crease of > 60 ms in the ramosetron group (Table 3).
The findings were consistent with the other calcula-
tion methods, including Fridericia’s, and Hodges for-
mulas (Additional file 1). Given the effect of
ramosetron on QTc interval, we have changed our
clinical practice to avoid ramosetron in patients at
high risk for developing TdP. Since intraoperative
QTc interval prolongation was common, we recom-
mend administering ramosetron at the end of surgery.
This study had several limitations. First, ramosetron
was administered at the beginning of anaesthesia in-
duction along with other drugs for induction of an-
aesthesia and possible drug-drug interactions may
have confounded the effects of ramosetron on QTc
interval. Moreover, a previous study indicated that
propofol, which was continuously infused during sur-
gery, may counteract the prolongation of QTc interval
[26]. However, induction anaesthetics, including
Fig. 4 Maximal change in QTc interval during surgery. Individual
data points are superimposed within each group
Table 3 Changes in QTc interval during the surgery
Number of patients (%)
Ramosetron (n = 51) Placebo (n = 52) Risk difference (95 % CI) P value
QTc interval prolongation > 500 ms 1 (2.0 %) 0 (0.0 %) 2.0 % (−1.8 to 5.8) 0.495
QTc interval increase > 60 ms 5 (9.8 %) 0 (0.0 %) 9.8 % (1.6 to 18.0) 0.021
QTc interval increase > 30 ms 13 (25.5 %) 12 (23.1 %) 2.4 % (−14.2 to 19.0) 0.775
Mean (SD) Mean difference (95 % CI)
Baseline QTc interval before injection (ms) 395.1 ± 19.7 397.2 ± 19.8 −2.09 (−9.85 to 5.66) 0.593
Maximal change in QTc interval (ms) 25.1 ± 22.0 17.5 ± 14.5 7.56 (0.34 to 14.78) 0.040
QTc interval at postoperative day 1 (ms) 428.9 ± 59.0 437.9 ± 56.3 −9.02 (−33.32 to 15.28) 0.463
Data are presented as mean ± SD or number (proportion). CI, confidence interval
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midazolam, vecuronium, and sufentanil, are known to
have minimal effects on QTc interval [27, 28], and we
did not use volatile anaesthetics that are known to
prolong QTc interval during this study [12–14]. Sec-
ond, intraoperative factors, some of which may be dif-
ficult to control for, may have affected QTc interval.
Surgical stress itself may also contribute to QTc inter-
val [29]. Third, the QTc interval varies between leads,
and the most appropriate lead to measure the QTc
interval has not been established.
Conclusion
Ramosetron (0.3 mg) administered during induction
of anaesthesia may increase maximal change in QTc
interval during OPCAB. Ramosetron should be used
with caution in high risk patients for developing TdP.
Additional file
Additional file 1: QTc interval by Fridericia’s formula and Hodges
formula. (DOCX 17 kb)
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Table 4 Postoperative in-hospital complications
Ramosetron (n = 51) Placebo (n = 52) RR (95 % CI) P value
Atrial fibrillation 11 (21.6 %) 14 (26.9 %) 0.80 (0.40 to 1.60) 0.647
Atrial flutter 1 (2.0 %) 1 (1.9 %) 1.02 (0.07 to 15.87) 1.000
Ventricular tachycardia 0 (0.0 %) 0 (0.0 %)
Ventricular fibrillation 0 (0.0 %) 0 (0.0 %)
Bradycardia (heart rate <50 beats/min) 0 (0.0 %) 2 (3.8 %) 0.495
Tachycardia (heart rate > 100 beats/min) 5 (9.8 %) 8 (15.4 %) 0.64 (0.22 to 1.82) 0.555
Death from cardiac causes 0 (0.0 %) 0 (0.0 %)
Myocardial infarction 0 (0.0 %) 0 (0.0 %)
Unplanned coronary revascularisation 0 (0.0 %) 1 (1.9 %) 1.000
Stroke 1 (2.0 %) 1 (1.9 %) 1.02 (0.07 to 15.87) 1.000
Intensive care unit length of stay (day) 2 (1 to 3) 2 (1 to 4) 0.912
Hospital length of stay (day) 9 (7 to 13) 8.5 (7 to 13.75) 0.350
Data are presented as number (proportion) or median (IQR). CI, confidence interval; RR, relative risk
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